Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer
Abstract The ATP-binding cassette (ABC) transporter protein, BCRP (breast cancer resistance protein)/ABCG2 pumps out some types of photosensitizers used in photodynamic therapy (PDT) and causes resistance to the antitumor effect of PDT. The purpose of this study was to investigate the association be...
Gespeichert in:
| Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2010-02, Vol.67 (2), p.198-204 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 204 |
|---|---|
| container_issue | 2 |
| container_start_page | 198 |
| container_title | Lung cancer (Amsterdam, Netherlands) |
| container_volume | 67 |
| creator | Usuda, Jitsuo Tsunoda, Yoshihiko Ichinose, Shuji Ishizumi, Taichirou Ohtani, Keishi Maehara, Sachio Ono, Shoutarou Tsutsui, Hidemitsu Ohira, Tatsuo Okunaka, Tetsuya Furukawa, Kinya Sugimoto, Yoshikazu Kato, Harubumi Ikeda, Norihiko |
| description | Abstract The ATP-binding cassette (ABC) transporter protein, BCRP (breast cancer resistance protein)/ABCG2 pumps out some types of photosensitizers used in photodynamic therapy (PDT) and causes resistance to the antitumor effect of PDT. The purpose of this study was to investigate the association between the expression of BCRP and the efficacy of PDT using Photofrin, or the second-generation photosensitizer, NPe6, for centrally located early lung cancers. Using human epidermoid carcinoma cells, A431 cells and the BCRP-overexpressing A431/BCRP cells, we examined the effects of BCRP expression on the effect of PDT by cell viability assay in vitro , and investigated the expression of BCRP by immunohistochemical analysis in 81 tumor samples obtained from patients with centrally located early lung cancers. The A431/BCRP cells were more resistant to Photofrin-PDT than A431 cells in vitro , and Fumitremorgin C, a specific inhibitor of BCRP, reversed the resistance. However, there was no significant difference in the antitumor effect of NPe6-PDT between these cells. All of the 81 centrally located early lung cancer lesions were BCRP-positive (2+, 45 lesions; 1+, 30 lesions) and all the patients were male and heavy smokers (>30 pack-years). The expression of BCRP significantly affected the efficacy of Photofrin-PDT in cancer lesions ≥10 mm in diameter ( P = 0.04). On the other hand, NPe6-PDT exhibited a strong antitumor effect, regardless of the expression status of BCRP. Photofrin may be a substrate of BCRP and be pumped out from the cells, therefore, BCRP may be a molecular determinant of the outcome of Photofrin-PDT. |
| doi_str_mv | 10.1016/j.lungcan.2009.04.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733858617</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S016950020900213X</els_id><sourcerecordid>733858617</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-f082dbfce3ab6b494c51c65faa3baa85f2b155e8f714ad04152a06fad41b00323</originalsourceid><addsrcrecordid>eNqFkktv1DAQxyMEokvhI4B8QbSHLH7Em-QCostTqkQFReJmTZwx9eLEi-1U2i_Sz4ujjUDiwsWWx795_WeK4imja0bZ5uVu7abxh4ZxzSlt17RaU8rvFSvW1LxshOD3i1Xm2lJm-0nxKMYdpaxmtH1YnLC2qmsq-Kq4uwgIMZEcSGMgAaONCcZE9sEntCM5u9h-uTonNhIgg3eoJweB9JgwDHacSW9IukHip6T9gPNzf-OT7w8jDFbPfwH2B3J29fb6nBgfiMYxBXDuQJzXkLAnCGF-5YaWQh4XDwy4iE-W-7T49v7d9fZjefn5w6ftm8tSSyZTaWjD-85oFNBtuqqtsllvpAEQHUAjDe-YlNiYmlXQ04pJDnRjoK9YR3P_4rR4cYyb2_01YUxqsFGjczCin6KqhWhks2F1JuWR1MHHGNCofbADhINiVM0TUTu1TETNE1G0Uln57PdsyTB1A_Z_vZYRZOD5AkDU4EzIAtj4h-NcSNq2MnOvjxxmPW4tBhW1xSxWbwPqpHpv_1vKq38iaGdHm5P-xAPGnZ_CmMVWTEWuqPo6r8-8PbTNBxPfxW_VxcNK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733858617</pqid></control><display><type>article</type><title>Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Usuda, Jitsuo ; Tsunoda, Yoshihiko ; Ichinose, Shuji ; Ishizumi, Taichirou ; Ohtani, Keishi ; Maehara, Sachio ; Ono, Shoutarou ; Tsutsui, Hidemitsu ; Ohira, Tatsuo ; Okunaka, Tetsuya ; Furukawa, Kinya ; Sugimoto, Yoshikazu ; Kato, Harubumi ; Ikeda, Norihiko</creator><creatorcontrib>Usuda, Jitsuo ; Tsunoda, Yoshihiko ; Ichinose, Shuji ; Ishizumi, Taichirou ; Ohtani, Keishi ; Maehara, Sachio ; Ono, Shoutarou ; Tsutsui, Hidemitsu ; Ohira, Tatsuo ; Okunaka, Tetsuya ; Furukawa, Kinya ; Sugimoto, Yoshikazu ; Kato, Harubumi ; Ikeda, Norihiko</creatorcontrib><description>Abstract The ATP-binding cassette (ABC) transporter protein, BCRP (breast cancer resistance protein)/ABCG2 pumps out some types of photosensitizers used in photodynamic therapy (PDT) and causes resistance to the antitumor effect of PDT. The purpose of this study was to investigate the association between the expression of BCRP and the efficacy of PDT using Photofrin, or the second-generation photosensitizer, NPe6, for centrally located early lung cancers. Using human epidermoid carcinoma cells, A431 cells and the BCRP-overexpressing A431/BCRP cells, we examined the effects of BCRP expression on the effect of PDT by cell viability assay in vitro , and investigated the expression of BCRP by immunohistochemical analysis in 81 tumor samples obtained from patients with centrally located early lung cancers. The A431/BCRP cells were more resistant to Photofrin-PDT than A431 cells in vitro , and Fumitremorgin C, a specific inhibitor of BCRP, reversed the resistance. However, there was no significant difference in the antitumor effect of NPe6-PDT between these cells. All of the 81 centrally located early lung cancer lesions were BCRP-positive (2+, 45 lesions; 1+, 30 lesions) and all the patients were male and heavy smokers (>30 pack-years). The expression of BCRP significantly affected the efficacy of Photofrin-PDT in cancer lesions ≥10 mm in diameter ( P = 0.04). On the other hand, NPe6-PDT exhibited a strong antitumor effect, regardless of the expression status of BCRP. Photofrin may be a substrate of BCRP and be pumped out from the cells, therefore, BCRP may be a molecular determinant of the outcome of Photofrin-PDT.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2009.04.002</identifier><identifier>PMID: 19477032</identifier><identifier>CODEN: LUCAE5</identifier><language>eng</language><publisher>Oxford: Elsevier Ireland Ltd</publisher><subject>Aged ; Aged, 80 and over ; ATP Binding Cassette Transporter, Sub-Family G, Member 2 ; ATP-Binding Cassette Transporters - genetics ; ATP-Binding Cassette Transporters - metabolism ; Biological and medical sciences ; Breast cancer resistant protein (BCRP) ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Cell Survival - drug effects ; Centrally located early lung cancer ; Dihematoporphyrin Ether - pharmacology ; Drug Resistance, Neoplasm - genetics ; Gynecology. Andrology. Obstetrics ; Hematology, Oncology and Palliative Medicine ; Humans ; Immunohistochemistry ; Lung cancer ; Lung Neoplasms - genetics ; Lung Neoplasms - metabolism ; Male ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Neoplasm Proteins - genetics ; Neoplasm Proteins - metabolism ; Photochemotherapy ; Photodynamic therapy (PDT) ; Photosensitizing Agents - pharmacology ; Pneumology ; Porphyrins - pharmacology ; Pulmonary/Respiratory ; Tumors ; Tumors of the respiratory system and mediastinum</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2010-02, Vol.67 (2), p.198-204</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2009 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2009 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c515t-f082dbfce3ab6b494c51c65faa3baa85f2b155e8f714ad04152a06fad41b00323</citedby><cites>FETCH-LOGICAL-c515t-f082dbfce3ab6b494c51c65faa3baa85f2b155e8f714ad04152a06fad41b00323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S016950020900213X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22350995$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19477032$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Usuda, Jitsuo</creatorcontrib><creatorcontrib>Tsunoda, Yoshihiko</creatorcontrib><creatorcontrib>Ichinose, Shuji</creatorcontrib><creatorcontrib>Ishizumi, Taichirou</creatorcontrib><creatorcontrib>Ohtani, Keishi</creatorcontrib><creatorcontrib>Maehara, Sachio</creatorcontrib><creatorcontrib>Ono, Shoutarou</creatorcontrib><creatorcontrib>Tsutsui, Hidemitsu</creatorcontrib><creatorcontrib>Ohira, Tatsuo</creatorcontrib><creatorcontrib>Okunaka, Tetsuya</creatorcontrib><creatorcontrib>Furukawa, Kinya</creatorcontrib><creatorcontrib>Sugimoto, Yoshikazu</creatorcontrib><creatorcontrib>Kato, Harubumi</creatorcontrib><creatorcontrib>Ikeda, Norihiko</creatorcontrib><title>Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>Abstract The ATP-binding cassette (ABC) transporter protein, BCRP (breast cancer resistance protein)/ABCG2 pumps out some types of photosensitizers used in photodynamic therapy (PDT) and causes resistance to the antitumor effect of PDT. The purpose of this study was to investigate the association between the expression of BCRP and the efficacy of PDT using Photofrin, or the second-generation photosensitizer, NPe6, for centrally located early lung cancers. Using human epidermoid carcinoma cells, A431 cells and the BCRP-overexpressing A431/BCRP cells, we examined the effects of BCRP expression on the effect of PDT by cell viability assay in vitro , and investigated the expression of BCRP by immunohistochemical analysis in 81 tumor samples obtained from patients with centrally located early lung cancers. The A431/BCRP cells were more resistant to Photofrin-PDT than A431 cells in vitro , and Fumitremorgin C, a specific inhibitor of BCRP, reversed the resistance. However, there was no significant difference in the antitumor effect of NPe6-PDT between these cells. All of the 81 centrally located early lung cancer lesions were BCRP-positive (2+, 45 lesions; 1+, 30 lesions) and all the patients were male and heavy smokers (>30 pack-years). The expression of BCRP significantly affected the efficacy of Photofrin-PDT in cancer lesions ≥10 mm in diameter ( P = 0.04). On the other hand, NPe6-PDT exhibited a strong antitumor effect, regardless of the expression status of BCRP. Photofrin may be a substrate of BCRP and be pumped out from the cells, therefore, BCRP may be a molecular determinant of the outcome of Photofrin-PDT.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>ATP Binding Cassette Transporter, Sub-Family G, Member 2</subject><subject>ATP-Binding Cassette Transporters - genetics</subject><subject>ATP-Binding Cassette Transporters - metabolism</subject><subject>Biological and medical sciences</subject><subject>Breast cancer resistant protein (BCRP)</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Centrally located early lung cancer</subject><subject>Dihematoporphyrin Ether - pharmacology</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - metabolism</subject><subject>Male</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Proteins - genetics</subject><subject>Neoplasm Proteins - metabolism</subject><subject>Photochemotherapy</subject><subject>Photodynamic therapy (PDT)</subject><subject>Photosensitizing Agents - pharmacology</subject><subject>Pneumology</subject><subject>Porphyrins - pharmacology</subject><subject>Pulmonary/Respiratory</subject><subject>Tumors</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkktv1DAQxyMEokvhI4B8QbSHLH7Em-QCostTqkQFReJmTZwx9eLEi-1U2i_Sz4ujjUDiwsWWx795_WeK4imja0bZ5uVu7abxh4ZxzSlt17RaU8rvFSvW1LxshOD3i1Xm2lJm-0nxKMYdpaxmtH1YnLC2qmsq-Kq4uwgIMZEcSGMgAaONCcZE9sEntCM5u9h-uTonNhIgg3eoJweB9JgwDHacSW9IukHip6T9gPNzf-OT7w8jDFbPfwH2B3J29fb6nBgfiMYxBXDuQJzXkLAnCGF-5YaWQh4XDwy4iE-W-7T49v7d9fZjefn5w6ftm8tSSyZTaWjD-85oFNBtuqqtsllvpAEQHUAjDe-YlNiYmlXQ04pJDnRjoK9YR3P_4rR4cYyb2_01YUxqsFGjczCin6KqhWhks2F1JuWR1MHHGNCofbADhINiVM0TUTu1TETNE1G0Uln57PdsyTB1A_Z_vZYRZOD5AkDU4EzIAtj4h-NcSNq2MnOvjxxmPW4tBhW1xSxWbwPqpHpv_1vKq38iaGdHm5P-xAPGnZ_CmMVWTEWuqPo6r8-8PbTNBxPfxW_VxcNK</recordid><startdate>20100201</startdate><enddate>20100201</enddate><creator>Usuda, Jitsuo</creator><creator>Tsunoda, Yoshihiko</creator><creator>Ichinose, Shuji</creator><creator>Ishizumi, Taichirou</creator><creator>Ohtani, Keishi</creator><creator>Maehara, Sachio</creator><creator>Ono, Shoutarou</creator><creator>Tsutsui, Hidemitsu</creator><creator>Ohira, Tatsuo</creator><creator>Okunaka, Tetsuya</creator><creator>Furukawa, Kinya</creator><creator>Sugimoto, Yoshikazu</creator><creator>Kato, Harubumi</creator><creator>Ikeda, Norihiko</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100201</creationdate><title>Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer</title><author>Usuda, Jitsuo ; Tsunoda, Yoshihiko ; Ichinose, Shuji ; Ishizumi, Taichirou ; Ohtani, Keishi ; Maehara, Sachio ; Ono, Shoutarou ; Tsutsui, Hidemitsu ; Ohira, Tatsuo ; Okunaka, Tetsuya ; Furukawa, Kinya ; Sugimoto, Yoshikazu ; Kato, Harubumi ; Ikeda, Norihiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-f082dbfce3ab6b494c51c65faa3baa85f2b155e8f714ad04152a06fad41b00323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>ATP Binding Cassette Transporter, Sub-Family G, Member 2</topic><topic>ATP-Binding Cassette Transporters - genetics</topic><topic>ATP-Binding Cassette Transporters - metabolism</topic><topic>Biological and medical sciences</topic><topic>Breast cancer resistant protein (BCRP)</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Centrally located early lung cancer</topic><topic>Dihematoporphyrin Ether - pharmacology</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - metabolism</topic><topic>Male</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Proteins - genetics</topic><topic>Neoplasm Proteins - metabolism</topic><topic>Photochemotherapy</topic><topic>Photodynamic therapy (PDT)</topic><topic>Photosensitizing Agents - pharmacology</topic><topic>Pneumology</topic><topic>Porphyrins - pharmacology</topic><topic>Pulmonary/Respiratory</topic><topic>Tumors</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Usuda, Jitsuo</creatorcontrib><creatorcontrib>Tsunoda, Yoshihiko</creatorcontrib><creatorcontrib>Ichinose, Shuji</creatorcontrib><creatorcontrib>Ishizumi, Taichirou</creatorcontrib><creatorcontrib>Ohtani, Keishi</creatorcontrib><creatorcontrib>Maehara, Sachio</creatorcontrib><creatorcontrib>Ono, Shoutarou</creatorcontrib><creatorcontrib>Tsutsui, Hidemitsu</creatorcontrib><creatorcontrib>Ohira, Tatsuo</creatorcontrib><creatorcontrib>Okunaka, Tetsuya</creatorcontrib><creatorcontrib>Furukawa, Kinya</creatorcontrib><creatorcontrib>Sugimoto, Yoshikazu</creatorcontrib><creatorcontrib>Kato, Harubumi</creatorcontrib><creatorcontrib>Ikeda, Norihiko</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Usuda, Jitsuo</au><au>Tsunoda, Yoshihiko</au><au>Ichinose, Shuji</au><au>Ishizumi, Taichirou</au><au>Ohtani, Keishi</au><au>Maehara, Sachio</au><au>Ono, Shoutarou</au><au>Tsutsui, Hidemitsu</au><au>Ohira, Tatsuo</au><au>Okunaka, Tetsuya</au><au>Furukawa, Kinya</au><au>Sugimoto, Yoshikazu</au><au>Kato, Harubumi</au><au>Ikeda, Norihiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2010-02-01</date><risdate>2010</risdate><volume>67</volume><issue>2</issue><spage>198</spage><epage>204</epage><pages>198-204</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><coden>LUCAE5</coden><abstract>Abstract The ATP-binding cassette (ABC) transporter protein, BCRP (breast cancer resistance protein)/ABCG2 pumps out some types of photosensitizers used in photodynamic therapy (PDT) and causes resistance to the antitumor effect of PDT. The purpose of this study was to investigate the association between the expression of BCRP and the efficacy of PDT using Photofrin, or the second-generation photosensitizer, NPe6, for centrally located early lung cancers. Using human epidermoid carcinoma cells, A431 cells and the BCRP-overexpressing A431/BCRP cells, we examined the effects of BCRP expression on the effect of PDT by cell viability assay in vitro , and investigated the expression of BCRP by immunohistochemical analysis in 81 tumor samples obtained from patients with centrally located early lung cancers. The A431/BCRP cells were more resistant to Photofrin-PDT than A431 cells in vitro , and Fumitremorgin C, a specific inhibitor of BCRP, reversed the resistance. However, there was no significant difference in the antitumor effect of NPe6-PDT between these cells. All of the 81 centrally located early lung cancer lesions were BCRP-positive (2+, 45 lesions; 1+, 30 lesions) and all the patients were male and heavy smokers (>30 pack-years). The expression of BCRP significantly affected the efficacy of Photofrin-PDT in cancer lesions ≥10 mm in diameter ( P = 0.04). On the other hand, NPe6-PDT exhibited a strong antitumor effect, regardless of the expression status of BCRP. Photofrin may be a substrate of BCRP and be pumped out from the cells, therefore, BCRP may be a molecular determinant of the outcome of Photofrin-PDT.</abstract><cop>Oxford</cop><pub>Elsevier Ireland Ltd</pub><pmid>19477032</pmid><doi>10.1016/j.lungcan.2009.04.002</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-5002 |
| ispartof | Lung cancer (Amsterdam, Netherlands), 2010-02, Vol.67 (2), p.198-204 |
| issn | 0169-5002 1872-8332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733858617 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Aged, 80 and over ATP Binding Cassette Transporter, Sub-Family G, Member 2 ATP-Binding Cassette Transporters - genetics ATP-Binding Cassette Transporters - metabolism Biological and medical sciences Breast cancer resistant protein (BCRP) Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects Centrally located early lung cancer Dihematoporphyrin Ether - pharmacology Drug Resistance, Neoplasm - genetics Gynecology. Andrology. Obstetrics Hematology, Oncology and Palliative Medicine Humans Immunohistochemistry Lung cancer Lung Neoplasms - genetics Lung Neoplasms - metabolism Male Mammary gland diseases Medical sciences Middle Aged Neoplasm Proteins - genetics Neoplasm Proteins - metabolism Photochemotherapy Photodynamic therapy (PDT) Photosensitizing Agents - pharmacology Pneumology Porphyrins - pharmacology Pulmonary/Respiratory Tumors Tumors of the respiratory system and mediastinum |
| title | Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T21%3A59%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Breast%20cancer%20resistant%20protein%20(BCRP)%20is%20a%20molecular%20determinant%20of%20the%20outcome%20of%20photodynamic%20therapy%20(PDT)%20for%20centrally%20located%20early%20lung%20cancer&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Usuda,%20Jitsuo&rft.date=2010-02-01&rft.volume=67&rft.issue=2&rft.spage=198&rft.epage=204&rft.pages=198-204&rft.issn=0169-5002&rft.eissn=1872-8332&rft.coden=LUCAE5&rft_id=info:doi/10.1016/j.lungcan.2009.04.002&rft_dat=%3Cproquest_cross%3E733858617%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733858617&rft_id=info:pmid/19477032&rft_els_id=1_s2_0_S016950020900213X&rfr_iscdi=true |